Genotype-informed longevity protocols

Knowing your genotype is not the same as knowing what to do about it. This gap sits at the heart of longevity genetics: variants associated with exceptional lifespan are well documented, but genotype-stratified intervention trials are, with one meaningful exception, almost entirely absent. Here is what the evidence supports, variant by variant.

APOE4: the most actionable finding, with a major asterisk

Roughly 14% of people carry at least one APOE4 allele, making it the most clinically relevant longevity variant in the literature. The mechanistic story is clearer than the therapeutic one.

At the cellular level, APOE4 activates a p38 MAPK pathway that triggers excess arachidonic acid extraction, producing LTB4 and driving microglial neuroinflammation, a process documented in human postmortem tissue, mouse models, and in vitro work [1]. This is independent of amyloid, and it provides a plausible rationale for anti-inflammatory interventions.

What it does not provide is a clean justification for DHA supplementation based on the argument that APOE4 disrupts brain DHA transport. PET imaging in young APOE4 carriers showed the opposite of what that narrative predicts: DHA brain uptake was higher in carriers than non-carriers (K*+16%, p=0.04; posterior cingulate +29%) [2]. Then PREVENT-E4, a 24-month RCT of 2g DHA/day in 368 adults aged 55-80, found that CSF DHA:AA ratio increased equally across genotypes (interaction p=0.71), confirming that DHA reaches the brain in APOE4 carriers at this age. Every cognitive, hippocampal, and cortical endpoint was null [3]. Quinn's earlier JAMA trial of 2g DHA/day for 18 months in 295 people with mild-to-moderate Alzheimer's disease found the same: no benefit in E4 carriers, no benefit overall [4].

The "DHA can't reach the APOE4 brain" justification is no longer valid. The neuroinflammation mechanism remains plausible, and Yassine's expert position is that earlier intervention (pre-50) and maintaining an omega-3 index above 8% may matter, but this is expert opinion, not trial evidence [5]. PREVENT-E4 studied people aged 55-80; the earlier-window question is open. A Mediterranean-pattern diet targeting the cPLA2/LTB4 pathway has strong cardiovascular primary support and mechanistic logic for APOE4 carriers, but no APOE4-stratified brain-outcome RCT exists [1].

FOXO3A: mechanistic confirmation, not a protocol change

The FOXO3A rs2802292 G allele is associated with exceptional longevity across multiple ethnicities. In the Hawaii Japanese-American cohort, homozygous minor-allele carriers had an OR of 2.75 for reaching exceptional longevity versus major-allele homozygotes [6]. German centenarian data show an OR of approximately 1.26 [7], and an Italian cohort found OR 1.51 in men [8].

The mechanism runs through low insulin/IGF-1 signaling: reduced IIS keeps FOXO3 unphosphorylated, allowing nuclear translocation and activation of DNA repair, antioxidant enzymes (SOD, catalase), autophagy, and cell-cycle arrest programs. Barzilai's analysis suggests G-allele carriers activate this program constitutively, meaning non-carriers have the most to gain from lifestyle interventions that suppress IIS [9].

Caloric restriction, fasting, and exercise all engage the same pathway. Knowing your FOXO3A status does not change which interventions are worth doing; it clarifies the molecular mechanism behind why they matter. No genotype-stratified intervention RCT exists for this variant. Carrying the protective allele is not a license to skip the lifestyle work.

GHRd3: the IGF-1 lesson from an extreme model

The GH receptor exon-3 deletion (GHRd3), present in roughly 8-12% of the population, shows increasing d3/d3 homozygosity with age across four long-lived cohorts, with an estimated 10 additional years of lifespan. The effect is male-specific in mega-analysis. D3/d3 carriers are taller in youth (reflecting greater GH sensitivity) but show lower IGF-1 in late life [10]. Mechanistically, this converges on the same IIS-lowering pathway as FOXO3A.

The Laron syndrome data add a stark human proof of concept: 99 subjects with complete GHR loss of function showed zero cancer deaths and zero diabetes cases over 17 years [11]. This is a disease state with other serious complications and is not a therapeutic model, but it confirms that dramatically lowering IGF-1 in humans reduces cancer and metabolic disease incidence. GH therapy in aging, which raises IGF-1, works directly against the longevity mechanism this variant encodes [9].

Protocol change for GHRd3 carriers: none that isn't already best for everyone. IIS-lowering lifestyle interventions remain the conclusion.

CETP I405V: why you can't reverse-engineer a protective genotype

CETP I405V reduces CETP enzyme activity, produces larger HDL and LDL particles, and appears in roughly 20% of Ashkenazi Jewish centenarians versus 3% of controls [12]. Pharmaceutical companies spent a decade trying to replicate this effect pharmacologically. The results were definitive.

Torcetrapib, which raised HDL substantially, was halted in ILLUMINATE (n=15,067) when cardiovascular events increased (MACE HR 1.25) and mortality rose 58% [13]. Dalcetrapib showed a completely null MACE HR of 1.04 (95% CI 0.93-1.16) in dal-OUTCOMES (n=15,871) and was stopped for futility [14]. Evacetrapib produced the largest pharmacological CETP signal tested, +134% HDL-C and -37% LDL-C, and still registered a null MACE HR of 1.01 (0.91-1.11) in ACCELERATE (n=12,092) [15].

The protective genotype does not transfer to drug-mediated HDL elevation. The variant's biology likely runs through pleiotropic mechanisms that CETP inhibition cannot replicate. Using niacin, fibrates, or CETP inhibitors to chase a centenarian's HDL profile is not supported by outcome data [12, 13, 14, 15].

APOE2: reassuring, not actionable

About 12% of people carry the ε2/ε3 genotype. A 40-consortium meta-analysis (n=5,930 AD cases, 8,607 controls) found ε2/ε3 carriers have roughly 40% lower odds of Alzheimer's disease versus the ε3/ε3 reference (OR 0.6, 95% CI 0.5-0.8) [16]. UK Biobank data (n=379,703) show ε2/ε3 heterozygosity associated with -0.43 SD LDL and CAD OR 0.87 (95% CI 0.83-0.90) [17]. Finnish centenarian data show ε2 carrier frequency rising from 9% at ages 100-101 to 25% at age 104 and above (p-for-trend =.01) [18]. Shinohara's analysis of 24,661 NACC participants found the APOE2 survival advantage persists after adjustment for Alzheimer's pathology and cardiovascular factors [19].

Two important caveats: ε2/ε2 homozygotes are not doubly protected. Remnant lipoprotein accumulation in that genotype reverses the cardiovascular benefit [17]. And ε2/ε4 compound heterozygotes carry APOE4's dominant AD risk (OR 2.6 versus ε3/ε3 in the same Farrer data) [16].

For ε2/ε3 carriers: the protection is real at population scale across brain and cardiovascular endpoints. No APOE2-stratified intervention trial exists. Standard lipid management, exercise, sleep, and diet apply.

Where the evidence is contested

APOE4 and DHA transport. An older hypothesis held that APOE4 impairs DHA delivery to the brain, justifying supplementation. PET imaging in young carriers contradicted this for the 20s-to-early-middle-age window [2], and PREVENT-E4 contradicted it for ages 55-80 [3]. What remains open is whether DHA supplementation started earlier (before age 55) could have a different effect, that window was not studied in PREVENT-E4. Yassine's expert position supports earlier intervention as a hypothesis [5], but no trial has tested it. The null results at 55-80 do not prove futility at 35-50; they also do not support current supplementation on mechanistic grounds that are now contested.

FOXO3A sex specificity. The Italian centenarian cohort found the FOXO3A longevity association in men only [8], while the Hawaii and German cohorts show effects that are not clearly sex-restricted [6, 7]. Whether the protective effect is sex-modified or whether the Italian finding reflects cohort size and composition is unresolved.

References

1. Wang S, Yassine HN et al. 2022 Mol Neurodegen — cPLA2 hyperactivation in APOE4: p38 MAPK → cPLA2 → arachidonic acid extraction → LTB4 →… · PubMed 35705959
2. Yassine HN et al. 2017 Alz Res Ther — DHA brain uptake PET ([1-¹¹C]-DHA); n=22; young APOE4 carriers: global GM K* +16% (p=0.04), posterior… · PubMed 28335828
3. Yassine HN et al. 2026 (eBioMedicine) — PREVENT-E4 RCT peer-reviewed; n=368; 2g DHA/day × 24mo; primary: CSF DHA delivery … · PubMed 42315445
4. Quinn JF et al. — DHA 2g/day × 18mo in mild-to-moderate AD (JAMA 2010; n=295; overall null; APOE4 subgroup null; non-E4 exploratory trend only, post-hoc) · PubMed 21045096
5. Attia ep.147 — Hussein Yassine, MD: APOE4, brain health, and omega-3s
6. Willcox BJ et al. 2008 (PNAS) — FOXO3A rs2802292 G allele; OR=2.75 for longevity in Japanese-American men; IIS pathway; replicated across multiple… · PubMed 18765803
7. Flachsbart F, Nebel A et al. 2009 (PNAS) — FOXO3A rs2802292 G allele; German centenarians/nonagenarians (n=1,762); OR ~1.26; first European… · PubMed 19196970
8. Anselmi CV, Puca AA et al. 2009 (Rejuvenation Res) — FOXO3A Italian replication; Southern Italian centenarians; rs2802288 OR=1.51 (1.15–1.98),… · PubMed 19415983
9. Attia ep204 — Barzilai: metformin + centenarian genetics
10. Ben-Avraham D, Barzilai N et al. 2017 (Science Advances) — GHRd3 longevity; 4 cohorts n=841; d3/d3 homozygosity increases linearly with age… · PubMed 28630896
11. Guevara-Aguirre J, Longo VD et al. 2011 (Sci Transl Med) — 99 Laron syndrome subjects (Ecuador) vs 1,266 relatives; 17-year follow-up; 0 cancer… · PubMed 21325617
12. Barzilai N et al. 2003 (JAMA) — CETP I405V variant in ~20% centenarians vs ~3% controls; larger HDL/LDL particles; Ashkenazi Jewish cohort · PubMed 14559957
13. Barter PJ et al. (ILLUMINATE Investigators). 2007 (NEJM) — Torcetrapib in 15,067 high-risk patients on statin background; HDL +72%, LDL −25%;… · PubMed 17984165
14. Schwartz GG et al. (dal-OUTCOMES Investigators). 2012 (NEJM) — Dalcetrapib in 15,871 post-ACS patients; HDL +31%, LDL minimal change; primary MACE:… · PubMed 23126252
15. Lincoff AM et al. (ACCELERATE Investigators). 2017 (NEJM) — Evacetrapib in 12,092 high-risk patients; HDL +134%, LDL −37% — largest biomarker… · PubMed 28514624
16. Farrer LA, Cupples LA, Haines JL et al. 1997 (JAMA) — 40-consortium meta-analysis; n=5,930 AD + 8,607 controls; ε2/ε3 OR 0.6 (0.5–0.8) for AD vs… · PubMed 9343467
17. Kuo CL et al. 2020 (Aging Albany NY) — UK Biobank PheWAS; n=379,703 European-descent, 9.4y follow-up; ε2/ε3: LDL −0.43 SD, CAD OR 0.87 (0.83–0.90),… · PubMed 32511104
18. Frisoni GB, Louhija J, Brayne C, Inzitari D. 2001 (J Gerontol Series A) — Finnish Centenarians Study; all 179 Finnish centenarians in 1991; ε2… · PubMed 11213279
19. Shinohara M et al. 2020 (eLife) — NACC (n=24,661; 5,413 deaths) + apoE-TR mouse survival cohort (n=118); APOE2 survival advantage persists after… · PubMed 33074098